REGULUS THERAPEUTICS INC.

Analyst Reco. Regulus Therapeutics Inc.

Equities

RGLS

US75915K3095

Delayed Nasdaq Other stock markets 01:00:00 2024-07-03 pm EDT			5-day change	1st Jan Change
1.8 ^USD	+2.27%		-11.76%	+40.62%

Jul. 01	Regulus Therapeutics Inc.(NasdaqCM:RGLS) added to Russell 2000 Index	CI
Jul. 01	Regulus Therapeutics Inc.(NasdaqCM:RGLS) added to Russell 3000E Index	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Canaccord Genuity Raises Price Target on Regulus Therapeutics to $28 From $11, Maintains Buy Rating	Jun. 25	MT
HC Wainwright Raises Regulus Therapeutics Price Target to $10 From $9, Maintains Buy Rating	Jun. 25	MT
JonesTrading Starts Regulus Therapeutics With Buy Rating, $8 Price Target	May. 31	MT
Canaccord Genuity Trims Price Target on Regulus Therapeutics to $11 From $12, Maintains Buy Rating	Mar. 19	MT
Leerink Partners Initiates Regulus Therapeutics at Outperform Rating With $6 Price Target	Mar. 18	MT
Wells Fargo Adjusts Regulus Therapeutics Price Target to $3 From $2, Maintains Equal Weight Rating	Mar. 13	MT
Canaccord Genuity Raises Regulus Therapeutics' Price Target to $12 From $9, Keeps Buy Rating	23-09-21	MT
HC Wainwright Adjusts Price Target on Regulus Therapeutics to $9 From $20, Maintains Buy Rating	23-04-21	MT
Canaccord Genuity Starts Regulus Therapeutics at Buy With $9 Price Target	22-11-08	MT
Wedbush Adjusts Regulus Therapeutics' Price Target to $0.42 From $1 Following Private Equity Placement; Neutral Rating Kept	22-01-21	MT
REGULUS THERAPEUTICS : Cantor Fitzgerald Reinstates Regulus Therapeutics at Overweight with $2 Price Target	21-09-02	MT
REGULUS THERAPEUTICS : Wedbush Halves Regulus Therapeutics' PT to $1 From $2 on RGLD4326 Timeline for Autosomal Dominant Polycystic Kidney Disease; Neutral Rating Kept	21-05-14	MT
REGULUS THERAPEUTICS : HC Wainwright Adjusts Regulus Therapeutics' Price Target to $2 From $1.50, Maintains Buy Rating	21-05-14	MT
REGULUS THERAPEUTICS : Wedbush Adjusts Price Target on Regulus Therapeutics to $2 From $1, Maintains Neutral Rating	21-02-17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Protect and grow your investments with the help of our experts

Securing my Investments

fermer